← All trials
NCT01360762
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2011
- Primary completion
- Nov 1, 2015
- Completion date
- Nov 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 72
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Institute of Tropical Medicine, BelgiumLead sponsor
- University of GondarStudy director
- University of AntwerpStudy director
- Addis Ababa UniversityCollaborator
- University of GondarCollaborator
- Tigray Regional Health Bureau, Tigray RegionCollaborator
- Amhara Regional Health Bureau, Amhara RegionCollaborator
- Leishmania East Africa PlatformCollaborator
- Drugs for Neglected Diseases InitiativeCollaborator
- Medecins Sans FrontieresCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.